Victory Capital Management Inc. Has $5.05 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Victory Capital Management Inc. boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 112.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,609 shares of the company's stock after purchasing an additional 77,611 shares during the period. Victory Capital Management Inc. owned about 0.26% of Harmony Biosciences worth $5,045,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after buying an additional 436 shares during the last quarter. Mendota Financial Group LLC boosted its holdings in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after acquiring an additional 965 shares during the last quarter. KBC Group NV boosted its holdings in Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after acquiring an additional 819 shares during the last quarter. Quantbot Technologies LP purchased a new position in Harmony Biosciences in the third quarter valued at about $74,000. Finally, Avanza Fonder AB purchased a new position in Harmony Biosciences in the fourth quarter valued at about $145,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY traded down $0.11 during trading on Tuesday, hitting $34.21. The company had a trading volume of 33,311 shares, compared to its average volume of 511,898. The business's 50-day moving average is $36.40 and its 200 day moving average is $35.62. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The company has a market cap of $1.96 billion, a P/E ratio of 16.21, a PEG ratio of 0.47 and a beta of 0.82.

Remove Ads

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same period in the previous year, the business earned $0.45 EPS. The company's revenue was up 19.5% on a year-over-year basis. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Activity

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 19,293 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey Dierks sold 1,629 shares of the company's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock worth $2,831,679 in the last ninety days. Corporate insiders own 30.80% of the company's stock.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of analyst reports. Mizuho lifted their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price for the company. HC Wainwright reduced their price objective on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $50.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, February 25th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $53.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.